Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 0.36 below Tiziana Life Sciences Ltd's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Tiziana Life Sciences Ltd in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 3307.

Explain Quick Ratio?
How much Cash & cash equivalents TLSA�s has?
What are TLSA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

TLSA Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	55.03 %	-13.28 %	71.42 %	71.42 %	10.57 %
Y / Y Cash & cash equivalent Change	7.68 %	238.97 %	238.97 %	238.97 %	214.79 %
Quick Ratio MRQ	0.36	0.36	0.36	0.36	0.52
TLSA's Total Ranking	# 3307	#	#	#	#
Seq. Current Liabilities Change	0 %	0 %	0 %	55.03 %	-44.07 %
Seq. Cash & cash equivalent Change	0 %	0 %	0 %	7.68 %	214.79 %

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 444
Healthcare Sector	# 854
Overall Market	# 3307

Quick Ratio Statistics
High	Average	Low
8.25	1.91	0.01
0		(Dec 31 2017)

Financial Statements
Tiziana Life Sciences Ltd's Current Liabilities	$ 11 Millions	Visit TLSA's Balance sheet
Tiziana Life Sciences Ltd's Cash & cash equivalent	$ 4 Millions	Visit TLSA's Balance sheet
Source of TLSA's Sales		Visit TLSA's Sales by Geography

Cumulative Tiziana Life Sciences Ltd's Quick Ratio

TLSA's Quick Ratio for the trailling 12 Months

TLSA Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	34.91 %	25.55 %	29.75 %	15.08 %	0.53 %
Y / Y Cash & cash equivalent TTM Growth	120.54 %	232.92 %	-40.35 %	-73.84 %	-86.91 %
Quick Ratio TTM	0.36	0.39	0.3	0.27	0.22
Total Ranking TTM	# 4782	#	#	#	#
Seq. Current Liabilities TTM Growth	9.74 %	-4.03 %	12.32 %	14.05 %	2.12 %
Seq. Cash & cash equivalent TTM Growth	1.82 %	21.87 %	27.99 %	38.87 %	53.7 %

Quick ratio ranking by company, industry and sector >> Back to TLSA Financial Strength Comparisons >> Go to Compare TLSA Quick Ratio to its Competitors

News about Tiziana Life Sciences Ltd Quick Ratio

Pioneering Hope in ALS Treatment Tiziana Life Sciences Submits IND Application for Intranasal Foralumab

The landscape of drug development for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) is fraught with challenges, yet it is also imbued with the potential for groundbreaking advancements. On March 4, 2025, Tiziana Life Sciences, Ltd., a biotechnology company focused on innovative immunomodulation therapies, took a decisive step forward by filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial of its lead candidate, intranasal foralumab. This development not only signifies Tiziana’s commitment to advancing new treatment modalities for ALS but also showcases the competitive landscape in which it operates. Navigating ALS Treatment Challenges ALS is a devastating neurodegenerative disease characterized by the progressive degeneration of motor neurons, leading to muscle weakness and atrophy. The search for effective therapies has been an arduous journey, marked by high rates of clinical trial failures. Tiziana’s entry into this arena with intranasal foralumab a fully human, anti-CD3 monoclonal antibody may represent a novel strategy to modulate immune responses and potentially halt or reverse neurodegeneration. The support from the ALS Association underscores the anticipation surrounding this investigational therapy, offering hope to patients and families grappling with this challenging condition.

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2025 to $11.21 millions, cumulative Quick Ratio decreased to 0.36 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 491 other companies have achieved higher Quick Ratio than Tiziana Life Sciences Ltd. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 4782.

Explain Quick Ratio?
How much Cash & cash equivalents TLSA�s has?
What are TLSA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 492
Healthcare Sector	# 1008
Within the Market	# 4782

trailing twelve months Quick Ratio Statistics
High	Average	Low
8.25	3.28	0.03
(Dec 31 2021)		(Dec 31 2019)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Zymeworks Inc	0.97	$ 41.157 Millions	$ 42.318 Millions
Elite Pharmaceuticals Inc	0.96	$ 11.407 Millions	$ 11.840 Millions
Zomedica Corp	0.95	$ 9.017 Millions	$ 9.449 Millions
Ensysce Biosciences Inc	0.94	$ 4.310 Millions	$ 4.568 Millions
Organogenesis Holdings Inc	0.94	$ 93.679 Millions	$ 100.124 Millions
Abbott Laboratories	0.93	$ 8,939.000 Millions	$ 9,587.000 Millions
Beyondspring Inc	0.93	$ 12.561 Millions	$ 13.504 Millions
Tg Therapeutics Inc	0.92	$ 141.970 Millions	$ 153.760 Millions
Prestige Consumer Healthcare Inc	0.92	$ 97.884 Millions	$ 106.623 Millions
Nanobiotix S a	0.92	$ 59.080 Millions	$ 64.408 Millions
Collegium Pharmaceutical Inc	0.91	$ 386.679 Millions	$ 425.760 Millions
Ironwood Pharmaceuticals inc	0.89	$ 215.456 Millions	$ 243.145 Millions
Medicus Pharma Ltd	0.88	$ 8.705 Millions	$ 9.938 Millions
Serina Therapeutics Inc	0.86	$ 3.056 Millions	$ 3.563 Millions
Nls Pharmaceutics Ltd	0.86	$ 4.402 Millions	$ 5.139 Millions
Cormedix Inc	0.85	$ 157.330 Millions	$ 184.012 Millions
Oncolytics Biotech Inc	0.85	$ 5.202 Millions	$ 6.101 Millions
Axsome Therapeutics Inc	0.85	$ 322.933 Millions	$ 378.836 Millions
Integrated Biopharma Inc	0.85	$ 3.615 Millions	$ 4.248 Millions
Turn Therapeutics Inc	0.85	$ 5.085 Millions	$ 6.003 Millions
Harrow Inc	0.76	$ 72.927 Millions	$ 96.302 Millions
Lifevantage Corp	0.74	$ 20.201 Millions	$ 27.217 Millions
Supernus Pharmaceuticals inc	0.73	$ 128.448 Millions	$ 177.074 Millions
Evolus Inc	0.71	$ 53.826 Millions	$ 75.305 Millions
Geron Corporation	0.71	$ 79.440 Millions	$ 111.542 Millions
Karyopharm Therapeutics Inc	0.69	$ 63.744 Millions	$ 92.060 Millions
Eton Pharmaceuticals Inc	0.67	$ 25.942 Millions	$ 38.490 Millions
Pharming Group N v	0.66	$ 145.305 Millions	$ 221.690 Millions
Rein Therapeutics Inc	0.65	$ 3.215 Millions	$ 4.916 Millions
Journey Medical Corp	0.64	$ 24.090 Millions	$ 37.442 Millions

Date modified: 2026-07-07T13:55:16+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.